Clinical trials: Thymalfasin
HIV Infections
The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection
To determine the safety of thymosin alpha 1 given twice weekly in a regimen of daily oral zidovudine (AZT) and biweekly polyethylene glycolated interleukin-2 (PEG IL-2).
- Trial name
- NCT00001036
- Testing
- Thymalfasin, Interleukin-2, Polyethylene Glycolated, Zidovudine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Gastric Cancer
Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
This is a prospective, single-center, randomized controlled, phase II clinical trial. The study aims to enroll 48 patients with resectable, locally advanced gastroesophageal junction adenocarcinoma who have not received any…
- Trial name
- NCT07277439
- Testing
- Radiochemoimmunotherapy, Immunomodulation
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Chronic Hepatitis b
Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients
This is a multicenter, randomized, open-label control trial of two arms conducted at 10 centres in China.The aim was to investigate whether sequential combination therapy with Thymosin alpha 1 and entecavir is superior to…
- Trial name
- NCT03448744
- Testing
- Thymosin Alpha1, Entecavir
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Wen-hong Zhang
Breast Cancer, TNBC - Triple-Negative Breast Cancer
Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment
This is a prospective, open-label, single-center, phase II, randomized controlled clinical trial involving patients with triple-negative breast cancer who meet the criteria for neoadjuvant chemotherapy (T > 2 cm, N+).
- Conditions
- Breast Cancer, TNBC - Triple-Negative Breast Cancer, Immunotherapy
- Trial name
- NCT07884201
- Testing
- Thymalfasin
- Volunteers
- 572 people
- Sponsor
- Fudan University
Hepatitis B, Chronic
Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B
This trial is to assess the efficacy and safety of Polyethylene Glycol thymosin alpha1 (PEG-Tα1), a new long immunomodulator (Category 1.1 of Chemical Drugs) being developed from Hansoh Pharmaceutical of China, in combination…
- Trial name
- PEG-Tα1 (NCT02366247)
- Testing
- PEG-Tα1, Adefovir
- Where
- 32 sites in China
- Volunteers
- 463 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Stage II Colorectal Cancer, Stage III Colorectal Cancer
Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer
For high-risk stage II and stage III colorectal cancer, even after radical resection and postoperative adjuvant chemo/radiotherapy, 30-40% of patients will still have recurrence and metastasis.
- Trial name
- NCT05086614
- Testing
- Thymosin Alpha1
- Where
- China
- Volunteers
- 2,500 people
- Sponsor
- Fudan University